궤양성 대장염 시장 기회, 성장 촉진 요인, 산업 동향 분석, 예측(2025-2034년)

The Global Ulcerative Colitis Market reached USD 8 billion in 2024 and is set to experience steady expansion, with a projected CAGR of 5.6% from 2025 to 2034. This growth is largely fueled by the increasing prevalence of ulcerative colitis, which continues to rise due to urbanization, evolving dietary habits, and environmental changes. As more people adopt Westernized lifestyles, factors such as poor diet, stress, and pollution have contributed to a higher incidence of inflammatory bowel diseases (IBD), including ulcerative colitis. With millions affected worldwide, the demand for effective and long-term treatment solutions is on the rise.

Advancements in medical research have led to the development of novel therapies that offer better disease management and improved patient outcomes. Pharmaceutical companies are actively investing in new drug formulations, including biologics and JAK inhibitors, to provide more targeted treatments. Additionally, healthcare systems are placing greater emphasis on early diagnosis and intervention, leading to increased patient awareness and timely medical care. The growing focus on patient-centric treatment plans, including personalized medicine and combination therapies, is also driving innovation within the market. Regulatory approvals for new drugs and expanded indications for existing medications are further contributing to market growth, creating lucrative opportunities for drug manufacturers and healthcare providers.

The market is categorized by drug type into aminosalicylates, biologics, corticosteroids, Janus kinase (JAK) inhibitors, immunosuppressants, and others. In 2024, the aminosalicylates segment generated USD 2.8 billion, reflecting its widespread use as a first-line treatment for mild to moderate ulcerative colitis. These anti-inflammatory drugs are highly effective in reducing symptoms and maintaining remission, making them a preferred option for many patients. Their ability to provide long-term relief without significant side effects has contributed to their strong market presence. With the increasing diagnosis rate of mild cases, the demand for aminosalicylates remains robust, ensuring their continued dominance in the market.

The method of administration plays a critical role in patient preference and treatment compliance. The market is segmented into oral and injectable therapies, with oral medications capturing a 52.2% share in 2024. Many commonly prescribed treatments, including aminosalicylates, JAK inhibitors, and immunosuppressants, are available in oral formulations, making them a convenient option for patients. The ease of self-administration, cost-effectiveness, and reduced need for frequent medical visits make oral drugs the preferred choice. Pharmaceutical companies continue to refine drug delivery systems, enhancing the bioavailability and efficacy of oral treatments, further strengthening this segment's position in the market.

The United States ulcerative colitis market was valued at USD 3 billion in 2024, making it one of the largest regional contributors to global market growth. The high prevalence of ulcerative colitis in the U.S. has driven significant demand for advanced treatment options. A well-established healthcare infrastructure, increased funding for research and development, and a proactive approach to disease awareness have accelerated market expansion.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of ulcerative colitis
    • 3.2.1.2 Expanding treatment options
    • 3.2.1.3 Increasing awareness and diagnosis
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Aminosalicylates
• 5.3 Biologics
• 5.4 Corticosteroids
• 5.5 Janus kinase (JAK) inhibitors
• 5.6 Immunosuppressants
• 5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Proctosigmoiditis
• 6.3 Ulcerative proctitis
• 6.4 Left-sided colitis
• 6.5 Pancolitis or universal colitis
• 6.6 Fulminant colitis

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AbbVie
• 10.2 Bausch Health Companies
• 10.3 Bristol Myers Squibb
• 10.4 Eli Lilly and Company
• 10.5 Johnson & Johnson
• 10.6 Merck
• 10.7 Mitsubishi Tanabe Pharma Corporation
• 10.8 Novartis
• 10.9 Pfizer
• 10.10 Sun Pharmaceutical Industries
• 10.11 Takeda Pharmaceutical Company Limited
• 10.12 Teva Pharmaceutical Industries